Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849570 | 0.83 | CSF1R (0.48) | PTGDR2ALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL21566543 | 0.80 | BRD4 (0.41) | BRD4PTGDR2ALDH1A1KDM4ETDP1 | |
| SCHEMBL17457424 | 0.80 | BRD4 (0.41) | BRD4PTGDR2ALDH1A1KDM4ETDP1 | |
| SCHEMBL16112010 | 0.78 | BRD4 (0.44) | BRD4ALDH1A1KDM4ETDP1HPGD | |
| SCHEMBL9269170 | 0.73 | ALDH1A1 (0.50) | ALDH1A1KMT2AKDM4ETDP1MEN1 | |
| SCHEMBL5529505 | 0.72 | ALDH1A1 (0.81) | ALDH1A1KDM4ERECQLKDRHPGD | |
| SCHEMBL13295322 | 0.72 | MEN1 (0.77) | ALDH1A1KMT2AKDM4ETDP1MEN1 | |
| SCHEMBL17464689 | 0.72 | BRD4 (0.57) | BRD4PTGDR2ALDH1A1KMT2AKDM4E | |
| SCHEMBL17807864 | 0.71 | BRD4 (0.58) | BRD4 | |
| SCHEMBL4842523 | 0.70 | CSF1R (0.58) | PTGDR2ALDH1A1KMT2AKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | BRPF3, BRD3, BRDT | BRD4 4/4885PTGDR2 3293/4885ALDH1A1 4430/4885 |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | BRPF3, BRD3, BRDT | BRD4 4/4885PTGDR2 3293/4885ALDH1A1 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.